SUCAMPO PHARMACEUTICALS
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and... Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.
SUCAMPO PHARMACEUTICALS
Industry:
Biotechnology Health Care
Founded:
1996-01-01
Address:
Bethesda, Maryland, United States
Country:
United States
Website Url:
http://www.sucampo.com
Total Employee:
51+
Status:
Active
Contact:
3019613440
Email Addresses:
[email protected]
Total Funding:
300 M USD
Technology used in webpage:
Domain Not Resolving SPF IPv6 Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Microsoft IIS 10 CPanel DMARC
Similar Organizations
Curtiss Healthcare
Curtiss Healthcare is a biopharmaceutical company.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-04-03 | Vtesse | Vtesse acquired by Sucampo Pharmaceuticals | N/A |
| 2015-10-31 | R-Tech Ueno | R-Tech Ueno acquired by Sucampo Pharmaceuticals | N/A |
Official Site Inspections
http://www.sucampo.com
- Host name: sucampo.com
- IP address: 146.214.96.210
- Location: St Louis United States
- Latitude: 38.6249
- Longitude: -90.4496
- Metro Code: 609
- Timezone: America/Chicago
- Postal: 63131
More informations about "Sucampo Pharmaceuticals"
Sucampo Pharmaceuticals - Wikipedia
Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt. Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had …See details»
Sucampo | Mallinckrodt Pharmaceuticals
We are excited and equally committed to continuing Sucampo’s strong efforts to bring much-needed development therapies to patients suffering from rare diseases like Niemann-Pick Type C and Familial Adenomatous Polyposis. To …See details»
News Detail | Mallinckrodt Pharmaceuticals
Sucampo stockholders holding approximately 32% of the outstanding Sucampo shares have entered into a tender and support agreement for this transaction. Mallinckrodt expects …See details»
Sucampo Pharmaceuticals LLC - Drug pipelines, Patents ... - Patsnap
Explore Sucampo Pharmaceuticals LLC with its drug pipeline, therapeutic area, technology platform, 40 clinical trials, 30 news, and 12 literature, Technology Platform:Synthetic peptide, …See details»
Sucampo Pharmaceuticals LLC
了解Sucampo Pharmaceuticals LLC (Sucampo Pharmaceuticals LLC)公司的药物管线，治疗领域，技术平台，以及它的40项临床试验, 34篇新闻和11篇文献，技术平台:小分子化药，合成多 …See details»
Sucampo Pharmaceuticals - Contacts, Employees, Board Members, …
Sucampo Pharmaceuticals has 2 current employee profiles, including Chief Executive Officer Peter Greenleaf. Peter Greenleaf Chief Executive Officer Peter Lichtlen Senior Medical Officer …See details»
Sucampo Pharmaceuticals - Funding, Financials, Valuation
Sucampo Pharmaceuticals is registered under the ticker NASDAQ:SCMP . Their stock opened with $11.50 in its Aug 3, 2007 IPO. Sucampo Pharmaceuticals has acquired 2 organizations. …See details»
Sucampo Pharmaceuticals Inc - Company Profile and News
Company profile page for Sucampo Pharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
Sucampo Pharmaceuticals, Inc. - LinkedIn
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products ...See details»
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, …
Feb 13, 2018 STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today …See details»
Sucampo Pharmaceuticals - Craft
Sucampo Pharmaceuticals is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic, and …See details»
Sucampo Pharmaceuticals - PitchBook
Sucampo Pharmaceuticals General Information Description. Manufacturer and developer of specialized medicines. The company focuses on the development and commercialization of …See details»
Sucampo Pharmaceuticals - Fortune
Sucampo Pharmaceuticals stock chart. Sucampo Pharmaceuticals in Fortune Rankings. 100 Fastest-Growing Companies. 100 Fastest-Growing Companies. 100 Fastest-Growing …See details»
News Detail | Mallinckrodt Pharmaceuticals
Feb 13, 2018 STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today …See details»
R-Tech Ueno - Crunchbase Company Profile & Funding
R-Tech Ueno sells pharmaceuticals. It is a Japanese pharmaceutical company that manufactures AMITIZA for Sucampo and Sucampo's commercialization partners. It has a diverse pipeline of …See details»
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, …
STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has …See details»
Sucampo Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks
The intellectual property of Sucampo Pharmaceuticals includes 57 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, …See details»
Sucampo Pharmaceuticals: What Can Investors Learn From The …
Dec 29, 2017 The market’s reaction isn’t as robust as one would expect: Sucampo shares traded up only by $1.00 to $18.00 (for 5.88%). Nevertheless, the stock gained by $7.45 (over …See details»
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, …
Sucampo shares not validly tendered into the tender offer (subject to certain exceptions) have been cancelled and converted into the right to receive $18.00 per share, which is the same …See details»